{
    "clinical_study": {
        "@rank": "102571", 
        "arm_group": [
            {
                "arm_group_label": "Panel A: MK-8723 Very Low Dose in Healthy Participants", 
                "arm_group_type": "Experimental", 
                "description": "MK-8723 very low dose administered as a single intravenous (IV) infusion to healthy participants."
            }, 
            {
                "arm_group_label": "Panel B: MK-8723 Low Dose in Healthy Participants", 
                "arm_group_type": "Experimental", 
                "description": "MK-8723 low dose administered as a single IV infusion to healthy participants."
            }, 
            {
                "arm_group_label": "Panel C: MK-8723 Medium Dose in Healthy Participants", 
                "arm_group_type": "Experimental", 
                "description": "MK-8723 medium dose administered as a single IV infusion to healthy participants."
            }, 
            {
                "arm_group_label": "Panel D: MK-8723 Medium-High Dose in Healthy Participants", 
                "arm_group_type": "Experimental", 
                "description": "MK-8723 medium-high dose administered as a single IV infusion to healthy participants."
            }, 
            {
                "arm_group_label": "Panel E: MK-8723 High Dose in Healthy Participants", 
                "arm_group_type": "Experimental", 
                "description": "MK-8723 high dose administered as a single IV infusion to healthy participants."
            }, 
            {
                "arm_group_label": "Panel F: MK-8723 Medium Dose in ITP Participants", 
                "arm_group_type": "Experimental", 
                "description": "MK-8723 medium dose administered as a single IV infusion to participants with ITP."
            }, 
            {
                "arm_group_label": "Panel G: MK-8723 Medium-High Dose in ITP Participants", 
                "arm_group_type": "Experimental", 
                "description": "MK-8723 medium-high dose administered as a single IV infusion to participants with ITP."
            }, 
            {
                "arm_group_label": "Panel H: MK-8723 High Dose in ITP Participants", 
                "arm_group_type": "Experimental", 
                "description": "MK-8723 high dose administered as a single IV infusion to participants with ITP."
            }, 
            {
                "arm_group_label": "Matching Placebo to MK-8723", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1 of Study Part 1 and Study Part 2 in Panels A, B, C, D, E, F, G, H."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objectives of this study are to assess the safety and tolerability of single\n      rising doses of MK-8723 in healthy adult participants and adult participants with chronic\n      immune thrombocytopenia purpura (ITP) and to assess pharmacodynamics of MK-8723 in\n      participants with ITP."
        }, 
        "brief_title": "Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Immune Thrombocytopenia Purpura", 
        "condition_browse": {
            "mesh_term": [
                "Purpura", 
                "Thrombocytopenia", 
                "Purpura, Thrombocytopenic"
            ]
        }, 
        "detailed_description": {
            "textblock": "In Part 1 of the trial, safety and pharmacokinetics of MK-8723 will be evaluated in healthy\n      participants. In Part 2 of the trial, safety, pharmacokinetics, and pharmacodynamics will be\n      evaluated among participants with ITP. In Part 1, dose escalation will occur in up to 5\n      serial panels of partcipants (Panels A, B, C, D, and E); each participant will receive a\n      single intravenous (IV) dose of MK-8723 (or placebo). In Part 2, dose escalation will occur\n      in up to 3 serial panels of participants with ITP (Panels F, G and H); each participant will\n      receive a single IV dose of MK-8723 (or placebo), once safety and tolerability of the\n      corresponding dose is shown in Part 1."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (Part 1):\n\n          -  Female participants must be non-pregnant, non-breast feeding, and of non-childbearing\n             potential;\n\n          -  Has a Body Mass Index (BMI) <=32 kg/m^2;\n\n          -  Has a body weight >= 50 kg and <= 100 kg;\n\n          -  Has been judged to be in good health based on medical history, physical examination,\n             vital sign measurements, electrocardiogram (ECG), and laboratory safety tests;\n\n          -  Non-smoker or has not used nicotine or nicotine-containing products for at least 3\n             months;\n\n        Inclusion Criteria (Part 2):\n\n          -  Has been diagnosed with ITP at least 3 months prior;\n\n          -  Female ITP participants must be non-pregnant, non-breast feeding, and either of 1)\n             non-childbearing potential or 2) must have serum beta human chorionic gonadotropin\n             (HGC) level consistent with a non-pregnant state, and agree to use acceptable\n             contraception from pretrial period until 84 days postdose;\n\n          -  Has a BMI <=36 kg/m^2;\n\n          -  Has been judged to be in good health, other than ITP diagnosis, based on medical\n             history, physical examination, vital sign measurements, ECG, and laboratory safety\n             tests;\n\n        Exclusion Criteria (Part 1):\n\n          -  Has a history or clinically significant endocrine, gastrointestinal, cardiovascular,\n             hematological, hepatic, immunological, renal, respiratory, genitourinary, or major\n             neurological abnormalities or diseases;\n\n          -  Has a history of cancer (malignancy);\n\n          -  Has a history of significant multiple and/or severe allergies or has had an\n             anaphylactic reaction or significant intolerability to prescription or\n             non-prescription drugs or food;\n\n          -  Is positive for hepatitis B surface antigen, hepatitis C antibodies, or human\n             immunodeficiency virus (HIV);\n\n          -  Has had major surgery or donated or lost 1 unit of blood in the 4 weeks prior;\n\n          -  Has participated in another investigational trial within 4 weeks (12 weeks for\n             biologics);\n\n          -  Has received a live virus vaccination within 42 days or plans to receive such while\n             participating in the trial;\n\n          -  Is unable to refrain from or anticipates the use of any medication, including\n             prescription and non-prescription drugs and herbal remedies from 2 weeks prior and\n             for the duration of the trial;\n\n          -  Consumes greater than 3 glasses of alcoholic beverages per day;\n\n          -  Consumes greater than 6 servings of caffeine-containing beverages per day;\n\n          -  Is currently a regular user of any illicit drugs or has a history of drug and/or\n             alcohol abuse within 3 months;\n\n          -  Has a history of ITP or other autoimmune disease;\n\n          -  Has an active infection that is clinically significant;\n\n        Exclusion Criteria (Part 2):\n\n          -  Has a comorbid and significant hematological or immunological disorder;\n\n          -  Has a history of significant multiple and/or severe allergies or has had an\n             anaphylactic reaction or significant intolerability to prescription or\n             non-prescription drugs or food;\n\n          -  Is positive for hepatitis B surface antigen, hepatitis C antibodies, or HIV;\n\n          -  Has had major surgery or donated or lost 1 unit o f blood within 4 weeks;\n\n          -  Has participated in another investigational trial within 4 weeks (12 weeks for\n             biologics);\n\n          -  Has a history of ITP unresponsive to intravenous immunoglobulin (IVIG);\n\n          -  Has had systemic corticosteroid use within 1month (with the exception of stable low\n             dose oral corticosteroids);\n\n          -  Has had systemic IVIG or other systemic immunomodulatory therapy within 3 months;\n\n          -  Has received a thrombopoietin receptor antagonist within 3 months;\n\n          -  Is unable to refrain from using thrombopoietin receptor agonists and/or systemic\n             immune modulatory medications throughout the study;\n\n          -  Has received a live virus vaccine within 42 days prior or plans to receive such\n             during the trial;\n\n          -  Consumes greater than 3 alcoholic beverages per day;\n\n          -  Consumes greater than 6 servings of caffeine-containing beverages per day;\n\n          -  Is currently a regular user of any illicit drugs or has a history of drug and/or\n             alcohol abuse within 3 months;\n\n          -  Has clinical evidence of bleeding or coagulopathy including petechial rash, easy\n             bruising, or excessive gingival bleeding with routine dental hygiene;\n\n          -  Has an active infection that is clinically significant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963260", 
            "org_study_id": "8723-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Panel A: MK-8723 Very Low Dose in Healthy Participants", 
                    "Panel B: MK-8723 Low Dose in Healthy Participants", 
                    "Panel C: MK-8723 Medium Dose in Healthy Participants", 
                    "Panel D: MK-8723 Medium-High Dose in Healthy Participants", 
                    "Panel E: MK-8723 High Dose in Healthy Participants", 
                    "Panel F: MK-8723 Medium Dose in ITP Participants", 
                    "Panel G: MK-8723 Medium-High Dose in ITP Participants", 
                    "Panel H: MK-8723 High Dose in ITP Participants"
                ], 
                "description": "MK-8723 administered as a single IV infusion.", 
                "intervention_name": "MK-8723", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Matching Placebo to MK-8723", 
                "description": "Matching placebo to MK-8723 administered as a single IV infusion.", 
                "intervention_name": "Matching Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Gary Jankelowitz", 
                    "phone": "61 2 8988 8246"
                }, 
                "facility": {
                    "address": {
                        "city": "North Ryde", 
                        "country": "Australia"
                    }, 
                    "name": "Merck Sharp & Dohme"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ofer Sharon", 
                    "phone": "972 9 9539310"
                }, 
                "facility": {
                    "address": {
                        "city": "Hod Hasharon", 
                        "country": "Israel"
                    }, 
                    "name": "Merck Sharp & Dohme Co. Ltd."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Israel"
            ]
        }, 
        "number_of_arms": "9", 
        "official_title": "A Two-Part, Single Rising Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of MK-8723 in Healthy Adults and Patients With Immune Thrombocytopenia Purpura", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: National Health and Medical Research Council", 
                "Israel: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants Experiencing an Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 84 days"
            }, 
            {
                "measure": "Number of Participants Discontinuing Study Due to An AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 84 Days"
            }, 
            {
                "measure": "Participant Platelet Response Rate to MK-8723", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963260"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area Under the Curve (AUC[0-\u221e]) of MK-8723 Among Healthy Participants and Participants With ITP", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 28"
            }, 
            {
                "measure": "Maximum Serum Concentration (Cmax) of MK-8723 Among Healthy Participants and Participants With ITP", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 28"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}